Status:
COMPLETED
Nalmefene Smoking Cessation Study
Lead Sponsor:
Somaxon Pharmaceuticals
Conditions:
Smoking Cessation
Eligibility:
All Genders
25-65 years
Phase:
PHASE2
Brief Summary
To determine if nalmefene is safe and effective in smoking cessation.
Detailed Description
Single centered, randomized, placebo-controlled,double-blind, outpatient pilot study to evaluate the efficacy, safety and tolerability of 2 doses of nalmefene on smoking cessation.
Eligibility Criteria
Inclusion
- Smokers in good general health self reporting more than 15 cigarettes per day
Exclusion
- \-
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT00202696
Start Date
September 1 2005
End Date
March 1 2006
Last Update
May 19 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905